![](http://datasheet.mmic.net.cn/370000/TDA21302_datasheet_16738575/TDA21302_24.png)
CoreControl
TM
Page 24 of 25
DS-CoreControl-TDA21302
Revision History
Datasheet DS-CoreControl-TDA21302
Actual Release: V1.2 Date: 10.04.2004
Previous Release: V1.1 Date: 10.01.04
Page of
actual Rel.
Page of
prev. Rel.
Subjects changed since last release
17
17
C
C1
= 6,6 nF,
C
C2
= 33 pF =>
C
C2
= 6,6 nF,
C
C1
= 33 pF
10
10
VID table correction VID4 1
0 from 1,0375V to 1,0875v
For questions on technology, delivery and prices please contact the Infineon Technologies Offices in
Germany or the Infineon Technologies Companies and Representatives worldwide: see the address list
on the last page or our webpage at
http://www.infineon.com/DCDC
Opti
MOS
and
Opti
MOS II
are trademarks of Infineon Technologies AG.
Edition 2004-01-10
Published by Infineon Technologies AG,
St.-Martin-Strasse 53,
D-81541 München
Infineon Technologies AG 2004.
All Rights Reserved.
Attention please!
The information herein is given to describe certain components and shall not be considered as warranted characteristics.
Terms of delivery and rights to technical change reserved.
We hereby disclaim any and all warranties, including but not limited to warranties of non-infringement, regarding circuits, descriptions and charts
stated herein.
Infineon Technologies is an approved CECC manufacturer.
Information
For further information on technology, delivery terms and conditions and prices please contact your nearest Infineon Technologies Office in Germany
or our Infineon Technologies Representatives worldwide (see address list).
Warnings
Due to technical requirements components may contain dangerous substances. For information on the types in question please contact your nearest
Infineon Technologies Office.
Infineon Technologies Components may only be used in life-support devices or systems with the express written approval of Infineon Technologies,
if a failure of such components can reasonably be expected to cause the failure of that life-support device or system, or to affect the safety or
effectiveness of that device or system. Life support devices or systems are intended to be implanted in the human body, or to support and/or
maintain and sustain and/or protect human life. If they fail, it is reasonable to assume that the health of the user or other persons may be
endangered.
We listen to Your Comments
Any information within this dokument that you feel is wrong, unclear or missing at all
Your feedback will help us to continously improve the quality of this dokument.
Please send your proposal (including a reference to this dokument) to:
mcdoku.comment@infineon.com